Metabolic reprogramming-a breakthrough point in overcoming resistance to BRAF mutant melanoma targeted therapy...

Area of Science:

• Oncology
• Cancer Metabolism
• Drug Resistance

Background:

• Targeted therapies like BRAF and MEK inhibitors are used for BRAF-mutant melanoma.
• These therapies can induce metabolic reprogramming in melanoma cells, leading to acquired resistance.
• Understanding these metabolic adaptations is crucial for overcoming treatment failure.

Purpose of the Study:

• To systematically review the mechanisms of therapy-induced metabolic reprogramming in BRAF-mutant melanoma.
• To explore potential combinatorial strategies targeting metabolic vulnerabilities.
• To identify key metabolic targets for novel therapeutic approaches.

Main Methods:

• Literature review of studies on BRAF-mutant melanoma and targeted therapy.
• Analysis of metabolic pathway alterations in response to BRAF/MEK inhibition.
• Identification of key regulatory factors and metabolic targets.

Main Results:

• Melanoma cells exhibit increased lactate accumulation, enhanced oxidative phosphorylation, and elevated glutamine utilization.
• Activation of the kynurenine pathway and increased fatty acid synthesis are observed.
• These metabolic shifts suppress ferroptosis and activate alternative signaling pathways, conferring resistance.

Conclusions:

• Metabolic reprogramming is a key mechanism of resistance to targeted therapy in BRAF-mutant melanoma.
• Targeting metabolic vulnerabilities, such as specific enzymes and pathways, offers promising therapeutic strategies.
• Combinatorial approaches combining metabolic inhibitors with BRAF/MEK inhibitors may overcome drug resistance.